Sotatercept · Winrevair
Protein / enzyme therapeutic
Evidence outlook
Approved: Pulmonary Arterial Hypertension
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Heart Failure · Phase 3 · investigational in the US
Also approved (3)
- Treatment of pulmonary arterial hypertension
- WINREVAIR® (sotatercept) is indicated: • In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II, III or IV (see 14 Clinical Trials).
- Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III and IV.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STELLAR NCT04576988 · Pulmonary Arterial Hypertension This was a randomized, quadruple-blind, placebo-controlled trial with 323 treated participants and a clinical primary efficacy endpoint. The primary 6-minute walk distance comparison favored sotatercept and was statistically significant (p<0.001), supporting a strong evidence grade. Registry: NCT04576988 | 3 | Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24); Number of Participants Who Experienced an Adverse Event (AE) (Up to approximately 24 weeks); Number of Participants Who Discontinued Study Treatment Due to an AE (Up to approximately 24 weeks) 2022-08-26 | Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) | Reliable signal | link ↗ |
View 3 more trials
ZENITH NCT04896008 · Pulmonary Arterial Hypertension ZENITH was a randomized, double-blind, placebo-controlled Phase 3 trial in 172 patients with pulmonary arterial hypertension in WHO functional class III or IV and a high 1-year risk of death, adding sotatercept or placebo to maximum background therapy. The primary endpoint was time to first death, lung transplantation or hospitalization for worsening PAH. Events occurred in 17.4% on sotatercept vs 54.7% on placebo (HR 0.24, P<0.001), and the trial stopped early for efficacy at a prespecified interim analysis. The primary was met. Source: Humbert et al., NEJM 2025. Registry: NCT04896008 | 3 | Time to First Confirmed Morbidity or Mortality Event (Up to approximately 31 months) 2024-07-26 | First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025). | Partial signal | link ↗ |
NCT05818137 NCT05818137 · Pulmonary Arterial Hypertension The study treated 46 participants in a single open-label group without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate measure of change in pulmonary vascular resistance, so the reported improvement cannot be separated from background therapy or other time-related effects. Registry: NCT05818137 | 3 | Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24 (Baseline and Week 24); Number of Participants Who Experienced an Adverse Event (AE) (Up to ~24 weeks); Number of Participants Who Discontinued Study Intervention Due to AEs (Up to ~24 weeks) 2024-03-12 | Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24 (Baseline and Week 24): Sotatercept - Primary Treatment Period 417.2 dynes*sec/cm^5 (range 235.2 to 812.8) | Weak signal | link ↗ |
SOTERIA NCT07218029 · Pulmonary Arterial Hypertension Registry: NCT07218029 | 3 | Number of Participants Who Experience an Adverse Event (AE) (Up to approximately 90 months); Number of Participants Who Discontinue Study Treatment Due to an AE (Up to approximately 86 months); Number of Participants with Detectable Anti-Drug Antibodies (ADAs) (Up to approximately 88 months); Laboratory parameters (Hematology): Concentration of Platelets and Hemoglobin (Up to approximately 88 months); Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT) (Up to approximately 86 months); Change From Baseline in Body Weight (Baseline and up to approximately 86 months); Change From Baseline in Blood Pressure (Baseline and up to approximately 86 months); Change From Baseline in Electrocardiogram (ECG) (Baseline and up to approximately 86 months) 2028-12-07 | In progress: results expected 7 Dec 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Activin receptor type IIA (ActRIIA) drugs
LAE102, HS235, IMC-003. Compare all 4 Activin receptor type IIA (ActRIIA) drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sotatercept (Winrevair): this drug | Approved | Protein / enzyme therapeutic | Activin receptor type IIA (ActRIIA) | Reliable signal | NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025). | |
| Ambrisentan (Letairis) | Approved | Small molecule | Endothelin A receptor | Reliable signal | NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001). | |
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant) NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults. | |
| Epoprostenol (Flolan) | ApprovedUS marketing discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Macitentan (Opsumit) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier | |
| Riociguat (Adempas) | Approved | Small molecule | Soluble guanylate cyclase | Reliable signal | NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5) | |
| Sildenafil (Revatio) | Approved | Small molecule | PDE5 | Partial signal | NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). | |
| Tadalafil (Adcirca) | Approved | Small molecule | PDE5 | Weak signal | NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks. | |
| Treprostinil (Orenitram) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) | |
| Treprostinil (Remodulin) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | Featured results are safety only in this race | |
| Extended-Release Tacrolimus (VI-0106) | Phase 3 | Small molecule | Calcineurin | not yet graded | No reviewed efficacy summary in this indication | |
| Imatinib Mesylate Prodrug (IkT-001Pro) | Phase 3 | Small molecule | PDGFR (imatinib-class) | not yet graded | No reviewed efficacy summary in this indication | |
| Ralinepag | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. | |
| Seralutinib | Phase 3 | Small molecule | PDGFR/CSF1R/KIT (multi-kinase) | Partial signal | NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Udenafil (Zydena) | Phase 2/3 | Small molecule | PDE5 | Weak signal | No reviewed efficacy summary in this indication | |
| APL-9796 | Phase 2 | Monoclonal antibody | ZIP12 (zinc transporter) | not yet graded | No reviewed efficacy summary in this indication | |
| LAE102 | Phase 2(overall) | Monoclonal antibody | Activin receptor type IIA (ActRIIA) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ROC-101 | Phase 2 | Small molecule | Rho-associated kinase (ROCK, pan) | not yet graded | No reviewed efficacy summary in this indication | |
| Vasigrobart | Phase 2 | Monoclonal antibody | PDGF-B | not yet graded | No reviewed efficacy summary in this indication | |
| Zamicastat | Phase 2 | Small molecule | DBH | Weak signal | No reviewed efficacy summary in this indication | |
| HS235 | Phase 1/2 | Peptide | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| IMC-003 | Phase 1/2(overall) | Biologic (subtype unspecified) | Activin receptor type IIA (ActRIIA) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| F230 | —(overall) | Small molecule | Endothelin A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| GSK6792070 | —(overall) | Undisclosed | Activin signalling | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1) | |
| PF-07868489 | Discontinued | Protein / enzyme therapeutic | Bone morphogenetic protein 9 (BMP9) | Partial signal | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Winrevair (Sotatercept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
August 2027 (1)
What to watch
2028 (11)
January 2028 (2)
March 2028 (3)
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
June 2028 (1)
What to watch
September 2028 (2)
October 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
January 2029 (1)
What to watch
February 2029 (1)
What to watch
May 2029 (1)
What to watch
2030 (1)
January 2030 (1)
What to watch
2035 (1)
August 2035 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent